Screening of selective histone deacetylase inhibitors by proteochemometric modeling

BACKGROUND: Histone deacetylase (HDAC) is a novel target for the treatment of cancer and it can be classified into three classes, i.e., classes I, II, and IV. The inhibitors selectively targeting individual HDAC have been proved to be the better candidate antitumor drugs. To screen selective HDAC in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Dingfeng, Huang, Qi, Zhang, Yida, Zhang, Qingchen, Liu, Qi, Gao, Jun, Cao, Zhiwei, Zhu, Ruixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542186/
https://www.ncbi.nlm.nih.gov/pubmed/22913517
http://dx.doi.org/10.1186/1471-2105-13-212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542186/
https://www.ncbi.nlm.nih.gov/pubmed/22913517
http://dx.doi.org/10.1186/1471-2105-13-212

Ejemplares similares